Thymus Neuroendocrine Carcinoma — Trials

Thymus Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Novartis Pharmaceuticals
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06141369	Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)	recruiting	N/A	21	Shanghai Jiao Tong University School of MedicineOTHER	1	Apr 9, 2026	clinicaltrials

Data updated 22 days agoSource updated Apr 9, 2026source: clinicaltrials